EN DE
Watch Cardiol Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cardiol Therapeutics Inc (CRDL) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Cardiol Therapeutics Inc stock $0.63, price $1.02, that is 38.2% below the price, quality 33 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA14161Y2006

CT Cardiol Therapeutics Inc logo Thin data Nov 10, 2026

Cardiol Therapeutics Inc

CRDL · US
Very expensive, weak quality

Our calculation puts a fair price 38% below what the stock costs today.

Fair value $0.6300 · Strongly overvalued
Quality 33/100
Weak Growth (revenue YoY −20.9 %/yr in USD)
Negative free cash flow
Trails peers (0/7)
Narrow moat 0/100
Thin data
Estimate
Watch Cardiol Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$4.86 $0.4510 Fair Value $0.6300 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.4510 – $4.86 · fair‑value band $0.4700 – $0.7900 · the $1.02 price screens above the $0.6300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Cardiol Therapeutics in your weekly email

Every Wednesday you see whether Cardiol Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.

Show moreShow less

Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Stock analysis

Cardiol Therapeutics Inc (CRDL) currently trades at $1.02, while our estimate is $0.6300, 38% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.4700 (bear) to $0.7900 (bull), the price of $1.02 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Cardiol Therapeutics Inc reported revenue of C$0 in FY2025 versus C$62.3K in FY2021. Reported net income was −C$33.8M in FY2025.

Key figures

Market cap $142M Micro · EPS (TTM) $−0.2500 · Return on equity −190% · Return on assets (EBIT) −86.9% (5-year average) · Free cash flow −$23.9M · Net cash $21.3M.

What moves the price

The share trades about 55% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −38%, CRDL screens richer than that median.

Fair Value

Bear $0.4700 Fair Value $0.6300 Bull $0.7900
Price $1.02 · Downside -38.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 20
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CRDL screens overvalued: fair value 38% below the price. Compare with Merck KGaA →

Compare Cardiol Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −38.2% · Below median
Profitability
Return on assets −143.2% · Bottom 25%
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 7.95× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs CRDL
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs CRDL
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs CRDL
Haleon plc HLN $9.06 $8.62 −5% vs CRDL
Merck KGaA MRK €149.35 €109.18 −27% vs CRDL
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs CRDL
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs CRDL
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs CRDL
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs CRDL
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs CRDL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cardiol Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cardiol Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/CRDL

Frequently asked questions

Is Cardiol Therapeutics Inc (CRDL) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.6300 versus a price of $1.02, about 38% lower (overvalued).
What is the fair value of CRDL?
Our estimate for Cardiol Therapeutics Inc is $0.6300 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.02.
What is the quality score of CRDL?
Cardiol Therapeutics Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cardiol Therapeutics Inc (CRDL)?
Our calculated price target is the estimate of $0.6300 (as of Nov 10, 2026). Cautious scenario $0.4700, optimistic scenario $0.7900. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cardiol Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $0.6300, about 38% lower versus a price of $1.02 (overvalued). Cautious scenario $0.4700, optimistic scenario $0.7900. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Cardiol Therapeutics Inc (CRDL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cardiol Therapeutics Inc it is $0.6300 per share (as of Nov 10, 2026), against a price of $1.02.
Is Cardiol Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CRDL trades above its calculated fair value: price $1.02, fair value $0.6300, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRDL?
No. The price is what the market pays today ($1.02); the fair value is what the company's own numbers justify ($0.6300). For Cardiol Therapeutics Inc the two are $0.3900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cardiol Therapeutics Inc worth?
The market values Cardiol Therapeutics Inc at about $142M (market capitalisation, as of Nov 10, 2026). Per share that is $1.02; our models calculate a fair value of $0.6300 per share.
What do the bullish and bearish scenarios say about CRDL?
Our models span a range for Cardiol Therapeutics Inc: cautious scenario $0.4700, base $0.6300, optimistic $0.7900 per share (as of Nov 10, 2026, price $1.02). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cardiol Therapeutics Inc (CRDL)?
Balance-sheet figures for Cardiol Therapeutics Inc (as of Nov 10, 2026): return on equity −190.2%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is CRDL from its 52-week high?
Cardiol Therapeutics Inc trades at $1.02, about 55% below its 52-week high of $2.29 and 10% above the low of $0.9260 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6300 is for.
Which stocks are comparable to Cardiol Therapeutics Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cardiol Therapeutics Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $1.02, calculated fair value $0.6300 (−38%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Cardiol Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cardiol Therapeutics Inc (CRDL)?
The closing price on Nov 10, 2026 was $1.02. Our estimate is $0.6300, about 38% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cardiol Therapeutics Inc right now?
The price sits above even our optimistic bull case ($0.7900). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Cardiol Therapeutics Inc

How large is the market capitalisation of Cardiol Therapeutics Inc (CRDL)?
The market capitalisation of Cardiol Therapeutics Inc is $142M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Cardiol Therapeutics Inc (CRDL)?
Earnings per share at Cardiol Therapeutics Inc are $−0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cardiol Therapeutics Inc (CRDL)?
The return on equity (ROE) of Cardiol Therapeutics Inc is −190% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cardiol Therapeutics Inc (CRDL)?
On an EBIT basis the return on assets of Cardiol Therapeutics Inc is −86.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Cardiol Therapeutics Inc (CRDL) generate?
The free cash flow of Cardiol Therapeutics Inc is −$23.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cardiol Therapeutics Inc (CRDL) hold?
Cardiol Therapeutics Inc holds more cash than debt, $21.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Cardiol Therapeutics Inc in the live analysis

One click puts Cardiol Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.